CD19 and precursor B-cell acute lymphoblastic leukemia: More recently, the development of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieved a major milestone in the treatment of R/R B-ALL and added another option to the arsenal against B-ALL.